Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INCYTE CORPORATION

(INCY)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
84.36 USD   +0.90%
02/01Insider Sell: Incyte
MT
01/31Piper Sandler Starts Incyte at Overweight With $100 Price Target
MT
01/30Insider Sell: Incyte
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about INCYTE CORPORATION
02/01Insider Sell: Incyte
MT
01/31Piper Sandler Starts Incyte at Overweight With $100 Price Target
MT
01/30Insider Sell: Incyte
MT
01/30Insider Sell: Incyte
MT
01/24Incyte to Present at Upcoming Investor Conference
BU
01/17Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
BU
01/13RBC Lifts Price Target on Incyte to $86 From $85, Maintains Outperform Rating
MT
01/09Incyte : JP Morgan Healthcare Conference Presentation
PU
01/09Transcript : Incyte Corporation Presents at 41st Annual J.P. Morgan Healthcar..
CI
01/06Insider Sell: Incyte
MT
01/05Transcript : Incyte Corporation Presents at Goldman Sachs Annual Healthcare C..
CI
01/03Wells Fargo Raises Price Target on Incyte to $75 From $72, Keeps Equalweight Rating
MT
2022Insider Sell: Incyte
MT
2022Insider Sell: Incyte
MT
2022Incyte to Present at Upcoming Investor Conferences
BU
More most relevant news
All news about INCYTE CORPORATION
02/01Insider Sell: Incyte
MT
01/31Piper Sandler Starts Incyte at Overweight With $100 Price Target
MT
01/30Insider Sell: Incyte
MT
01/30Insider Sell: Incyte
MT
01/24Incyte to Present at Upcoming Investor Conference
BU
01/17Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
BU
01/13Forte Biosciences, Inc. - Mr. David Gryska Appointed to Forte Biosciences Board of Dire..
AQ
01/13RBC Lifts Price Target on Incyte to $86 From $85, Maintains Outperform Rating
MT
01/10BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Cl..
MT
01/09Incyte : JP Morgan Healthcare Conference Presentation
PU
More news
News in other languages on INCYTE CORPORATION
02/01Vente d'initiés : Incyte
01/30Vente d'initiés : Incyte
01/30Vente d'initiés : Incyte
01/10BriaCell annonce la délivrance d'un nouveau brevet, des conseils sur le calendrier de l..
01/06Vente d'initiés : Incyte
01/05Morphosys: 2023 nur im besten Fall Wachstum beim Krebsmittel Monjuvi
01/05Morphosys erwartet kaum Wachstum bei Blutkrebsmittel Monjuvi
2022Vente d'initiés : Incyte
2022Vente d'initiés : Incyte
2022Incyte annonce des données provenant de deux études LIMBER évaluant des traitements com..
More news
Analyst Recommendations on INCYTE CORPORATION
01/31Piper Sandler Starts Incyte at Overweight With $100 Price Target
MT
01/13RBC Lifts Price Target on Incyte to $86 From $85, Maintains Outperform Rating
MT
01/03Wells Fargo Raises Price Target on Incyte to $75 From $72, Keeps Equalweight Rating
MT
2022RBC Capital Raises Incyte's Price Target to $82 From $77, Keeps Outperform Rating
MT
2022Morgan Stanley Adjusts Price Target on Incyte to $77 From $76, Keeps Equalweight Rating
MT
More recommendations
Press releases
01/24Incyte to Present at Upcoming Investor Conference
BU
01/17Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
BU
01/13Forte Biosciences, Inc. - Mr. David Gryska Appointed to Forte Biosciences Board of Dire..
AQ
01/09Incyte : JP Morgan Healthcare Conference Presentation
PU
2022Incyte to Present at Upcoming Investor Conferences
BU
More press releases
Upcoming event on INCYTE CORPORATION